Board Member
Azora Therapeutics, Inc. (DE) (AZR)Equibles does not estimate personal net worth.
Get an email with a short summary when Azora Therapeutics, Inc. (DE) publishes a filing, an earnings call transcript or a press release.
Get AZR alertsCary J. Claiborne is recorded as COO at Azora Therapeutics, Inc. (DE) (AZR) since December 8, 2021 and Board Member at Azora Therapeutics, Inc. (DE) (AZR) since November 2, 2021. The newest filing on record that lists Cary J. Claiborne as Board Member at Azora Therapeutics, Inc. (DE) (AZR) is dated August 24, 2026. Azora Therapeutics, Inc. (DE) reported in an 8-K filed October 28, 2026 that Cary J. Claiborne was terminated as President and Chief Executive Officer, effective October 28, 2026. Azora Therapeutics, Inc. (DE) reported in an 8-K filed September 18, 2026 that Cary J. Claiborne was appointed Class II director, effective September 17, 2026. Azora Therapeutics, Inc. (DE) reported in an 8-K filed August 23, 2022 that Cary J. Claiborne was appointed President and Chief Executive Officer, effective August 18, 2022. The proxy statement of Azora Therapeutics, Inc. (DE) reports total compensation of $466,763 for Cary J. Claiborne in fiscal 2021, including a base salary of $15,200. Disclosed compensation is on record for 2 fiscal years. Cary J. Claiborne has spoken on 1 investor event across 1 company, most recently for Azora Therapeutics, Inc. (DE) on June 11, 2026. Azora Therapeutics, Inc. (DE) is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Azora Therapeutics, Inc. (DE) includes Matthew Davidson (CEO), Matthew Davidson, Ph.D. (CEO), William B. Stilley (CEO) and 7 others.
“In connection with Dr. Davidson’s appointment as President and Chief Executive Officer, Dr. Davidson will succeed Cary J. Claiborne, whose employment was terminated effective as of the Effective Date.”
“The Company's stockholders elected each of Cary J. Claiborne and Robertson H. Gilliland as a Class II director, to serve until the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, with the following votes:”
“Today marks an important milestone for Adal Pharmaceuticals. We are very pleased to announce our acquisition of Azor Therapeutics and a concurrent private placement of up to $64 million.”
2021-12-08–present
2021-11-02–present
Last confirmed August 24, 2026
2022-08-18–2026-10-28
Biotechnology · Healthcare
COO, Board Member
2021-11-02–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Azora Therapeutics, Inc. (DE) (AZR) | Chief Executive Officer since August 18, 2022; Former Chief Operating Officer and Member of the Board of Directors | $15,200 | $466,763 |
| 2020 | Azora Therapeutics, Inc. (DE) (AZR) | Chief Executive Officer since August 18, 2022; Former Chief Operating Officer and Member of the Board of Directors | — | — |
